Skip to main content
TipRanks
Go Ultimate75% OFF

Diamedica Therapeutics (DMAC) Q3 2026 Earnings Report

573 Followers

DMAC Q3 2026 EPS Results

Actual EPS
-$0.21
Consensus EPS
-$0.21
Beat/Miss
Missed by -$0.00
One Year Ago EPS
-$0.17

DMAC Q3 2026 Revenue Results

Actual Revenue
$0
Expected Revenue
$0
Beat/Miss
Met expectations
YoY Revenue Growth
―

Earnings Announcement Details

Quarter
Q3 2026
Date
11/12/2026
Time
After Close
Conference Call
Thursday, November 12, 2026
DMAC Upcoming Earnings

Diamedica Therapeutics's next earnings date is estimated for March 23, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

DMAC Q3 2026 Earnings Call
0:00 / 0:00

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 12, 2026|% Change Since:-14.04%|
Earnings Call Sentiment|Positive

The call was overall positive, driven by two major clinical milestones, completion of the initial FGR cohorts, progress toward the ReMedy2 interim analysis, expanding preeclampsia studies, and a stated cash runway into the fourth quarter of 2027. The positive clinical progress was tempered by declining cash and working capital, higher operating expenses and net losses, continued FDA nonclinical requirements, and the possibility that company-sponsored preeclampsia enrollment could move into early 2027.

Company Guidance

Management expects cash, cash equivalents and short term investments to fund planned clinical studies and corporate operations into the fourth quarter of 2027; research and development expenses will increase moderately relative to recent prior periods, while general and administrative expense will remain relatively steady compared with recent prior periods. Two additional preeclampsia studies are expected to begin enrollment by the end of 2026, each including up to 30 women. The company-sponsored phase 2 study should be starting here in the next few weeks, with enrollment this year, but worst case it should be early in 2027, including 3 dose levels, 6 patients per dose level, and an additional 12 patients at a selected dose. The ReMEDY2 DSMB is expected to complete its analysis in the first quarter of 2027; if the trial continues, the final enrollment target will range from 300 to 728 participants, with closer to 300 patients if the drug effect is comparable to phase 2 and the high end of 728 if the drug effect is closer to 6 percent.

  • Two Major Clinical Milestones AchievedDiaMedica completed enrollment in the first two cohorts of the investigator-sponsored Phase 2 early-onset fetal growth restriction study and enrolled the 200th participant in the pivotal Phase 2/3 ReMEDy2 acute ischemic stroke trial. ReMEDy2 thereby reached the prespecified enrollment threshold for its interim analysis.
  • Fetal Growth Restriction Cohorts CompletedThe first two FGR cohorts included 12 participants, with 6 treated at 5 micrograms per kg and 6 treated at 10 micrograms per kg. The company will present preliminary safety and clinical observations at a November 24 key opinion leader event.
  • Additional Preeclampsia Studies PlannedTwo additional investigator-sponsored preeclampsia studies are expected to begin enrollment by the end of 2026. One will include up to 30 women with early-onset preeclampsia receiving repeated subcutaneous dosing until delivery, and the other will include up to 30 women with late-onset or late-stage preeclampsia receiving continuous intravenous DM199 infusion.
  • Progress on Company-Sponsored Preeclampsia TrialHealth Canada authorized a protocol amendment in September for the open-label Phase 2 dose-finding study, preparations continued for enrollment at Canadian sites, and the company plans to expand the study into the United Kingdom subject to regulatory authorization. The approximately 30-patient study will evaluate three dose levels.
  • European Regulatory AuthorizationIn October, the Phase 2 early-onset preeclampsia study received conditional authorization from the European Medicines Agency, with consideration for full approval after country-specific ethical and site requirements.
  • Additional Reproductive Toxicology Study CompletedThe in-life portion of an additional rat reproductive toxicology study was completed during the third quarter, and DM199 was well tolerated by the animals. Pharmacokinetic and pharmacologic results were expected in the coming weeks for submission to the FDA.
  • ReMedY2 Interim Analysis AdvancingFollowing the required 90-day follow-up of the 200th participant, the independent DSMB will review the primary efficacy endpoint, defined as the proportion of participants with a modified Rankin Scale score of 0 to 1 at day 90. The DSMB analysis is expected in the first quarter of 2027.
  • Adaptive Stroke Trial Design Provides Enrollment FlexibilityIf ReMEDy2 continues after the interim analysis, the final enrollment target will range from 300 to 728 participants under the prespecified statistical plan. Management said a drug effect comparable to the Phase 2 result would imply a target closer to 300 patients, while a drug effect closer to 6 percent would imply a target toward the high end of 728.
  • Positive Prior Preeclampsia Observations CitedManagement reported that Part 1a of the investigator-sponsored preeclampsia trial showed rapid and sustained reductions in maternal systolic and diastolic blood pressure following DM199 treatment, along with pharmacodynamic effects and trends suggesting reduced uterine artery pulsatility.
  • Company Continues Global Clinical DevelopmentDiaMedica is continuing global expansion and preparation of clinical programs, including the ReMedY2 stroke trial, the Phase 2 preeclampsia study in Canada and the United Kingdom, additional reproductive toxicology testing, and preparations for a larger early-onset preeclampsia trial.
  • Cash Runway Extends Into Fourth Quarter of 2027As of September 30, 2026, DiaMedica had $34.9 million in cash, cash equivalents and short-term investments. Based on current plans, management expects these funds to support planned clinical studies and corporate operations into the fourth quarter of 2027.
  • General and Administrative Expense Remained Relatively StableGeneral and administrative expense was $2.4 million in the third quarter and $7.2 million for the first nine months of 2026, compared with $2.6 million and $7.3 million, respectively, in the corresponding 2025 periods. Management expects G&A expense to remain relatively steady compared with recent prior periods.

DMAC Earnings History

DMAC earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 23, 20272026 (Q4)-0.24--0.17――
Nov 12, 20262026 (Q3)-0.21-0.21-0.17-23.53% (-0.04)
Aug 10, 20262026 (Q2)-0.20-0.19-0.18-5.56% (-0.01)
May 06, 20262026 (Q1)-0.19-0.19-0.18-5.56% (-0.01)
Mar 30, 20262025 (Q4)-0.18-0.17-0.185.56% (+0.01)
Nov 12, 20252025 (Q3)-0.16-0.17-0.15-13.33% (-0.02)
Aug 12, 20252025 (Q2)-0.19-0.18-0.13-38.46% (-0.05)
May 13, 20252025 (Q1)-0.18-0.18-0.14-28.57% (-0.04)
Mar 17, 20252024 (Q4)-0.17-0.18-0.12-50.00% (-0.06)
Nov 13, 20242024 (Q3)-0.15-0.15-0.12-25.00% (-0.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed